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E-mail address: Jayanta.Debnath@ucsf.edu (J. DebnAutophagy, or cellular self-digestion, is activated in cancer cells in response to multiple stresses and
has been demonstrated to promote tumor cell survival and drug resistance. Nonetheless, genetic
evidence supports that autophagy functions as a tumor suppressor mechanism. Hence, the precise
role of autophagy during cancer progression and treatment is both tissue and context dependent.
Here, we discuss our current understanding of the biological functions of autophagy during cancer
development, overview how autophagy is regulated by cancer-associated signaling pathways, and
review how autophagy inhibition is being exploited to improve clinical outcomes.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction progression, such as nutrient starvation, the unfolded protein re-Macroautophagy (hereafter called autophagy) is an evolution-
arily conserved catabolic process where a cell self-digests its cyto-
plasmic contents (literally ‘‘eats itself”). In eukaryotic cells,
autophagy is a key mechanism for long-lived protein degradation
and organelle turnover, and serves as a critical adaptive response
that recycles energy and nutrients during starvation or stress [1].
Autophagy is tightly regulated by a limited number of highly con-
served genes called autophagy regulators (ATGs) (for AuTophaGy
gene). Originally identiﬁed in yeast, these landmark results have
led to numerous recent breakthroughs in mammals demonstrating
how autophagy critically regulates key physiological and patholog-
ical processes, including cancer initiation and progression. Autoph-
agy is activated in response to multiple stresses during cancerchemical Societies. Published by E
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ath).sponse (endoplasmic reticulum (ER) stress), and hypoxia; in addi-
tion, it is observed upon treatment of cancers with a wide
spectrum of cytotoxic and targeted chemotherapeutic agents [2].
The role of autophagy as a survival mechanism in response to these
diverse stressors has been well established. Moreover, it has be-
come increasingly clear that a basal level of autophagy serves
housekeeping functions vital for maintaining cellular homeostasis;
speciﬁcally, the failure to clear protein aggregates or damaged
organelles via autophagy has been implicated in multiple patho-
logical conditions, including cancer [3].
Based on these studies, autophagy has been proposed to pro-
mote the cellular ﬁtness of cancer cells; thus self-eating should
function unitarily as a tumor-promoting mechanism. However, ge-
netic evidence supports otherwise. Rather, autophagy can exert
important tumor suppressive functions. Clearly, several fundamen-
tal issues must be addressed to most effectively exploit autophagy
for therapeutic purposes against cancer. In this review, we summa-
rize the current understanding of autophagy in the context of
tumorigenesis and oncogenic transformation. We discuss the po-
tential mechanisms by which autophagy suppresses tumor forma-
tion, how autophagy is regulated by oncogenes and tumor
suppressors, and overview how autophagy is being exploited to
improve clinical outcomes.
2. Autophagy as a tumor suppressor mechanism
The role of autophagy as a tumor suppressor was ﬁrst broached
through genetic studies of Beclin1, the mammalian orthologue oflsevier B.V. All rights reserved.
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that is monoallelically deleted in a high percentage of human
breast, ovarian, and prostate cancers; furthermore, analysis of hu-
man tissue samples revealed decreased Beclin1 expression in hu-
man breast carcinomas compared to normal breast tissue.
Ectopic Beclin1 expression reduced cancer cell proliferation
in vitro and decreased tumorigenic potential in vivo, further sug-
gesting a role for autophagy in tumor suppression [4]. In support
of this notion, two groups demonstrated that heterozygous disrup-
tion of beclin1 promoted tumorigenesis in mice, albeit over an ex-
tended latency [5,6]. Mice lacking one copy of beclin1 suffered from
a high incidence of spontaneous tumors, including B cell lym-
phoma, hepatocellular carcinoma, and lung adenocarcinoma. These
reports provided the ﬁrst direct genetic evidence that beclin1/atg6
functions as a haploinsufﬁcient tumor suppressor.
In addition to Beclin1, the genetic alteration of other autoph-
agy-related genes has been found in various types of cancer. These
include the deletion of atg5, an essential autophagy gene, in natural
killer (NK) cell malignancies [7]; nonsense mutations in UV irradi-
ation Resistance-Associated Gene (UVRAG), a Beclin1-binding pro-
tein that positively regulates autophagy, in colon cancer cells [8],
and gastric carcinomas [9], and the downregulation of Bax-binding
protein-1 (Bif-1), another positive regulator of autophagy, in colon
adenocarcinomas [10]. In animal models, Atg4c knockout mice ex-
hibit increased susceptibility to ﬁbrosarcomas [11]. These ﬁndings
support that tumor suppression is a shared property of different
components of the autophagic pathway, rather than a phenotype
unique to disrupting any individual ATG.
How the suppression of autophagy leads to cancer remains un-
clear, although several potential mechanisms have emerged. First,Fig. 1. Diverse roles for autophagy in cancer progression and therapy. (A) The suppre
organelles, resulting in a cascade of increased oxidative stress, genome instability, and
apoptosis and autophagy are prone to necrosis in response to metabolic stress. Necrosi
favors primary tumor growth. (C) Autophagy promotes oncogene-induced senescence, a
survival in response to diverse stresses, including chemotherapy, metabolic stress, anda mounting body of work from Eileen White and colleagues dem-
onstrates an important role for autophagy in protecting cells from
genotoxic stress and maintaining genome integrity. Mouse epithe-
lial cells that are defective in both autophagy and apoptosis, due to
the loss of one copy of beclin1 combined with the overexpression of
Bcl-2, are more prone to necrosis during metabolic stress, yet par-
adoxically, these cells exhibit enhanced tumorigenic potential [12].
Notably, these studies demonstrate that autophagy defective cells
show a remarkable increase in DNA double strand breaks and gene
ampliﬁcation in response to metabolic stress compared to their
autophagy-competent counterparts [13]. In a 3D morphogenesis
assay using mammary epithelial cells derived from Beclin1 hetero-
zygous mice, accelerated cell death and increased DNA damage
was also observed in central acinar cells, where metabolic stress
occurred [14]. Based on these studies, White and colleagues raised
the hypothesis that defective autophagy may enhance DNA dam-
age, thus causing an increased mutation rate in cells that survive
metabolic stress, which ultimately leads to tumorigenesis. One ma-
jor caveat is that these experiments have been conducted in cells
harboring multiple genetic abnormalities, including the inactiva-
tion of the tumor suppressor p53, which is well-known for its abil-
ity to maintain genomic integrity [15]. As a result, one can argue
that defective autophagy most likely functions as a secondary
modiﬁer, rather than a fundamental driver, of genomic damage
during tumor progression. Nonetheless, additional studies point
to the molecular mechanism by which defective autophagy in-
duces genome damage. In response to metabolic stress, autophagy
incompetent cells have defects in protein turnover, resulting in the
accumulation of the scaffold protein p62/SQSTM, ER chaperones,
damaged mitochondria, and elevated reactive oxygen speciesssion of autophagy induces protein aggregates and the accumulation of damaged
ultimately, malignant transformation. (B) Tumor cells with combined defects in
s promotes inﬂammatory responses, notably the recruitment of macrophages, that
barrier to malignant transformation. (D) Autophagy induction promotes tumor cell
anoikis, which may facilitate drug resistance and metastasis.
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binding scaffold protein speciﬁcally degraded by autophagy [17], is
a signiﬁcant contributor to tumorigenesis. Taken together, these
ﬁndings delineate novel connections linking decreased autophagy
to tumorigenesis; autophagy suppression causes the accumulation
of damaged mitochondria and p62 protein aggregation, resulting in
a cascade of events involving increased oxidative stress, DNA dam-
age, and chromosomal instability, and ultimately leading to cancer
development (Fig. 1A).
The second potential mechanism of autophagy-mediated tumor
suppression is also based on the observation that when apoptosis
is blocked, autophagy incompetent cells are more prone to undergo
necrosis in response to metabolic stress whereas autophagy-com-
petent cells are more resistant to cell death [12]. Remarkably,
inﬂammatory cells inﬁltrate tumor sites in response to necrosis
resulting from hypoxia and metabolic stress, both of which com-
monly affect solid tumors. Although certain inﬂammatory cells,
such as cytotoxic T cells and NK cells are anti-metastatic, chronic
tumor inﬂammation associated with severe hypoxia and metabolic
stress generally favors pro-tumor immunity [18–20]. Importantly,
inﬁltration of pro-tumor inﬂammatory mediators, like macro-
phages, correlates with poor clinical prognosis, underscoring the
importance of understanding the biological mechanisms by which
tumor cells tip the balance in favor of pro-tumor immunity over
tumor suppressive immunity [20]. Thus, by limiting tumor cell
necrosis, autophagy may serve as a non-autonomous mechanism
for tumor suppression by preventing leukocyte inﬁltration of the
primary tumor site (Fig. 1B).
In addition, a recent study reports that autophagy is required
for the establishment of oncogene-induced senescence (OIS), pro-
viding an alternative mechanism of autophagy-mediated tumor
suppression [21]. Senescence is a state of irreversible cell cycle ar-
rest that limits the proliferation of damaged cells. OIS is induced by
aberrant hyper-proliferation signals from oncogenes, thus serving
as an early barrier to cancer development. Recent work demon-
strates that autophagy is activated during oncogene- and DNA
damage-induced senescence; RNAi-mediated depletion of atg5 or
atg7 facilitates the ability of cells to bypass OIS and delays senes-
cence-associated cytokine production, suggesting that autophagy
contributes to the establishment of senescence arrest (Fig. 1C).
These results also implicate that basal autophagy plays an impor-
tant role in restricting cell growth and proliferation during onco-
genic stress as well as precluding further genomic insults.
Despite these exciting experimental ﬁndings in cell-based and
mouse models, it is important to recognize that no direct evidence
exists showing that reduced or defective autophagy is a common
requirement for human cancer initiation. This is primarily because
the direct and quantitative detection of autophagy levels in human
tumor samples remains technically intractable.
3. Autophagy and tumor cell survival
Although reduced autophagy promotes certain aspects of tumor
formation, a minimal level of autophagy does appear to contribute
to the cellular ﬁtness and survival of established tumor cells in re-
sponse to various stresses (Fig. 1D). Because oncogenic cells have a
high demand for nutrients and oxygen to facilitate their high pro-
liferation rate, cells often encounter metabolic stress and hypoxia,
especially in poorly vascularized solid tumors. Accordingly, cells in
the interior of a tumor have higher levels of autophagy compared
to those at the margin, which protects them from both apoptosis
and necrosis [12]. In addition, a pro-survival effect of autophagy
may promote the later stages of cancer progression, such as dis-
semination and metastasis, the principal cause of cancer mortality.
For instance, detachment from extracellular matrix (ECM) inducesautophagy in epithelial cells, which protects them from cell death,
commonly termed anoikis. Tumor cells must overcome anoikis in
order to metastasize [22]. Furthermore, autophagy is upregulated
by the tumor suppressor ARHI (aplasia Ras homolog member I)
in ovarian cancer cells, which has been shown to promote in vivo
survival of dormant cells in the context of a tumor microenviron-
ment [23]. Finally, a large body of work also demonstrates that
autophagy serves as an important survival mechanism for cancer
cells during anti-cancer therapies, which we discuss in detail
below.
4. Molecular regulation of autophagy in cancer
4.1. mTORC1 dependent regulation of autophagy
The best known regulator of autophagy is mammalian target of
rapamycin (mTOR), a serine/threonine kinase conserved through-
out eukaryotes [24]. mTOR forms two complexes in mammalian
cells; of these, mTOR complex 1 (mTORC1) plays a central role in
sensing nutrient availability, mitogenic signals, and energy status.
Thus, it controls cell growth, protein translation, and cell prolifer-
ation [25]. The activity of mTORC1 is inversely correlated with
autophagy induction; in fact, rapamycin, a mTORC1 inhibitor, po-
tently induces autophagy, even in the presence of abundant nutri-
ents [24]. Furthermore, a variety of pathways that direct mTORC1
activation converge on the tuberous sclerosis complex (TSC) and
the Ras Homolog Enriched in Brain (Rheb), a small GTPase that
activates mTORC1 in its GTP-bound form [25]. TSC, which is com-
prised of two primary components, TSC1 (harmartin) and TSC2
(tuberin), has a GTPase activating protein (GAP) function that
hydrolyzes GTP, thereby negatively regulating Rheb and inhibiting
mTORC1 activity [26]. Importantly, TSC is primarily regulated via
phosphorylation downstream of diverse upstream pathways; these
phosphorylation events can be activating or deactivating, depend-
ing on speciﬁc residues that are phosphorylated on TSC1 or 2
(Fig. 2).
As the principal regulator of cell growth, mTORC1 is deregu-
lated in most human cancers [25]. Many of the signaling molecules
that regulate mTORC1 are found to be oncogenes and tumor sup-
pressors. Rheb is overexpressed in prostate cancer and co-operates
with PTEN haplo-insufﬁciency to promote tumorigenesis [27].
High Rheb activity, due to loss of TSC1, inhibits autophagy and sen-
sitizes cells to cell death induced by misfolded-proteins [28]. Most
importantly, activation of the class I phosphotidylinositol 3-kinase
(PI3K) and downstream components, such as the kinase AKT, have
been demonstrated to activate mTORC1. Enhanced PI3K activity is
often found through activating kinase mutations or gene ampliﬁca-
tion in cancers; such events should inhibit autophagy. In support,
the lipid products of class I PI3K, PI (3,4) P2 or PI (3,4,5) P3, sup-
press autophagy induction in colon cancer cells [29]. Furthermore,
mutational activation of AKT suppresses autophagy in response to
metabolic stress [12] whereas AKT kinase inhibition potently in-
duces autophagy through inactivating mTORC1 [30]. On the other
hand, overexpression of the tumor suppressor PTEN, the negative
regulator of PI3K/AKT pathway, induces autophagy [31]. Similarly,
ARHI, another tumor suppressor commonly lost in ovarian cancers,
induces autophagy via negatively regulating the PI3K pathway
[23].
4.2. LKB1–AMPK
The activation of autophagy has been proposed to play a critical
role in cell survival in response to reduced energy (ATP). The LKB1–
AMPK pathway links metabolism to cell growth control, and
increasing evidence supports a role for this signaling axis in con-
Fig. 2. Cancer-associated signaling pathways that regulate autophagy in mammalian cells. See text for details.
1430 N. Chen, J. Debnath / FEBS Letters 584 (2010) 1427–1435trolling autophagy [32]. LKB1–AMPK monitors intracellular energy
levels and sends signals to mTORC1 through TSC dependent and
independent mechanisms. During metabolic stress, the reduction
in ATP levels results in an elevated AMP/ATP ratio and activates
the energy-sensing kinase, LKB1, which subsequently phosphory-
lates and activates AMPK. An established connection to autophagy
downstream of these signals is through AMPK-mediated phosphor-
ylation of TSC, which results in the inactivation of mTORC1 and
induction of autophagy [33,34]. Still, various other TSC-indepen-
dent pathways may promote autophagy. First, AMPK has been
found to directly inhibit mTORC1 in a TSC-independent manner,
via direct phosphorylation of Raptor, an activating component of
mTORC1; this effect is LKB1-dependent and promotes cell survival
in response to energy stress, presumably through autophagy
induction [35]. In addition, the LKB1–AMPK axis can phosphorylate
and stabilize p27kip, a cyclin-dependent kinase inhibitor that in-
duces cell cycle arrest [36]. These studies also show that p27 is re-
quired for glucose starvation-induced autophagy and cell survival
downstream of LKB-AMPK. Because the relationship between p27
phosphorylation and mTORC1 in response to energy stress was
not evaluated in this study, it remains unknown whether p27 reg-
ulates autophagy through mTORC1 dependent or independent
pathways. Furthermore, cells expressing the oncogene simian virus
40 small T antigen are more resistant to glucose deprivation in-
duced cell death through activation of AMPK and autophagy [37].
4.3. Beclin1 complexes
Mammalian Beclin1 (ATG6) was originally identiﬁed as a Bcl-2
interacting protein [38]. Subsequent studies indicated that Beclin1
forms multi-molecular complexes with numerous proteins that
impact the induction or inhibition of autophagy (Fig. 2). Nonethe-
less, the core functions of Beclin1 in autophagy induction result
from its interactions with Vps34 and p150. Vps34 is a class III
PI3K that is regulated by p150 [39]. In addition, Beclin1/Vps34/
p150 interacts with UVRAG and Atg14 [40]. Although the exactmechanism by which these complexes promote autophagy is un-
clear, it has been shown that the interaction between Beclin1
and Vps34 is required for engaging Vps34 kinase activity in the
autophagic pathway [41,42].
Notably, UVRAG is a candidate tumor suppressor, which like Be-
clin1, is monoallelically deleted in human colon cancers [43].
Although expression of UVRAG alone has little effect on cell death,
over-expression of wild type, but not Beclin1-binding deﬁcient UV-
RAG, suppresses colon cancer cells growth in vitro and tumor for-
mation in vivo, suggesting the tumor suppressor function of
UVRAG requires its interaction with Beclin1. Nonetheless, another
binding partner of UVRAG, the C-Vps (class C Vps complex), a key
component of the endosomal fusion machinery, has also been
implicated in the regulation of autophagy, independent of Beclin1.
The interaction of the C-Vps complex with UVRAG promotes auto-
phagosome maturation and enhances the degradation of autopha-
gic cargo [44]. Thus, UVRAG may also positively regulate
autophagy by enhancing autophagosome maturation.
In addition to stimulating Beclin1/Vps34 activity, UVRAG also
facilitates Beclin1 interaction with other proteins implicated in
autophagy. One such protein is Bif-1, a potential tumor suppressor
that belongs to the endophilin family of proteins [45]. Loss of Bif-1
expression reduces Vps34 kinase activity and suppresses autoph-
agy induction in response to starvation. At a structural level, an
N-terminal Bin/Amphiphysin/Rvs (BAR) domain of Bif-1 is critical
for its role in autophagy regulation. Because BAR-domain contain-
ing proteins have been implicated in membrane binding and mem-
brane curvature, it has been speculated that Bif-1 may facilitate
autophagosome isolation membrane building [46]. In line with this
notion, Bif-1 co-localizes with Atg5 and LC3, suggesting its involve-
ment in early autophagosome formation.
Moreover, another binding partner of Beclin1 has been identi-
ﬁed as mammalian Atg14/Atg14L/Barkor, the mammalian ortho-
logue of yeast Atg14 [40,47–49]. Studies from four groups show
that mammalian Atg14 interacts with the Beclin1 complex and
positively regulates autophagy. Accordingly, the RNAi-mediated
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autophagic ﬂux in response to starvation. Studies reveal that Be-
clin1/Vps34/p150 forms two distinct complexes with Atg14 and
UVRAG in a mutually exclusive manner. These complexes regulate
autophagy at different steps, namely autophagosome formation
and maturation, respectively [40,47,48]. In addition, two groups
identiﬁed another molecule, called Rubicon, as a negative regulator
of autophagy, in association with Beclin1 complexes. Over-expres-
sion of Rubicon causes the aberrant expansion of late endosomes
and lysosomes, resulting in defects in autophagosome maturation.
Given that other Beclin1 complex components function as tumor
suppressors, dissecting the potential roles of Atg14 and Rubicon
in cancer development remains an important subject for future
study.
4.4. Members of Bcl-2 family
Bcl-2, the ﬁrst protein found to physically interact with Beclin1,
has been shown to possess an anti-autophagy function in addition
to its well-established role in apoptosis inhibition [38]. In addition
to Bcl-2, other anti-apoptotic Bcl-2 family proteins, such as Bcl-xL
and Mcl-1, are also capable of interacting with Beclin1 and sup-
pressing autophagy [50,51]. Because these anti-apoptotic proteins
are commonly over-expressed in cancer cells, autophagy inhibition
may have an additive effect on the oncogenic properties of these
Bcl-2 proteins. In support of this notion, RNAi-mediated depletion
of Bcl-2 is sufﬁcient to trigger autophagy and apoptosis in tumor
cells [52,53]. At a structural level, Beclin1 interacts with multi-do-
main Bcl-2 proteins via its BH3 domain and a BH3-receptor domain
on Bcl-2 proteins. Disruption of such interaction by a BH3-mimetic
agent, ABT737, or expression of ‘‘BH3-only” protein, such as Bad,
induces autophagy [50]. Importantly, the phosphorylation status
of either protein can interfere with this autophagy-regulating
interaction (Fig. 2). During nutrient starvation, JNK1 mediated
Bcl-2 phosphorylation dissociates Beclin1/Bcl-2 complex and in-
duces autophagy [54]. On the other hand, the tumor suppressor
DAPK1, directly phosphorylates the Beclin1 BH3 domain, promot-
ing the dissociation of the Beclin1/Bcl-xL complex and thus induc-
ing autophagy [55]. Moreover, the tumor suppressor ARF, a well-
established cell cycle regulator, can induce autophagy by binding
to Bcl-xL and thereby releasing Beclin1 [56].
In addition, certain pro-apoptotic proteins of the Bcl-2 family
have been implicated in autophagy regulation in different condi-
tions. Expression of BNIP3, a ‘‘BH3-only” Bcl-2 family protein, has
been found to disrupt the Beclin1/Bcl-2 interaction and induce the
autophagic degradation of mitochondria (mitophagy) in response
to hypoxia [57]. Furthermore, Puma, another ‘‘BH3-only” protein in-
ducedbyp53, inducesmitochondrial autophagy in response tomito-
chondrial perturbations in a Bax/Bak dependent manner [58].
4.5. p53-related regulators of autophagy
The transcription factor p53 is the most commonly mutated tu-
mor suppressor. p53 levels increase in multiple cancer-related
stress conditions, including DNA damage, oncogenic stress and hy-
poxia. In mammalian cells, p53 shuttles between the nucleus and
the cytoplasm; activated p53 translocates to the nucleus and in-
duces target gene expression, resulting in cell cycle arrest, DNA re-
pair or apoptosis. Although p53 is best known as a nuclear
transcription factor, recent work indicates that cytoplasmic p53
mediates mitochondrial outer membrane permeabilization and
apoptosis [59].
Similarly, p53 plays a dual role in autophagy regulation depend-
ing on its subcellular location. The role of nuclear p53 in inducing
autophagy appears to primarily arise from the transcriptional con-
trol of mTOR pathway regulators (Fig. 2). Indeed, multiple p53 tar-get genes, such as AMPKb, TSC2, and PTEN, are all known negative
regulators of mTORC1 [60]. Remarkably, two p53 target genes, ses-
trin1 and sestrin2, have been identiﬁed as a critical link between
p53 activation and mTORC1 activity [61]. Sestrin is induced by
p53 in response to DNA damage and oxidative stress, which inhib-
its mTORC1 activity by stimulating AMPK-mediated TSC activation.
Interestingly, Sestrin expression is able to override oncogene-med-
iated mTOR activation and cell growth, providing another mecha-
nism of p53-mediated tumor suppression. Subsequent work
corroborates that Sestrin2 is required for autophagy induction in
response to various stress inducers, including nutrient starvation
and rapamycin [62].
Another target of p53, DRAM (damage-regulated autophagy
modulator), has been shown to positively regulate autophagy
[63]. DRAM is essential for p53-mediated autophagy and apoptosis
in response to DNA damage agents, and the ectopic expression of
DRAM is sufﬁcient to activate autophagy but has little effect on
apoptosis. The role of DRAM as a tumor suppressor is suggested
by the ﬁnding that DRAM expression is downregulated in cancer
cells due to promoter hyper-methylation [63]. The exact mecha-
nism of DRAM-mediated autophagy activation remains unclear.
Paradoxically, p53 has also been found to suppress autophagy
independently of its transcriptional function in the nucleus [64].
Rather, cytoplasmic p53 inhibits autophagy in response to multiple
autophagy-inducing agents. Many stresses, such as nutrient starva-
tion, rapamycin, or ER stress, promote p53 degradation; hence, p53
stabilization suppresses autophagy mediated by these stressors.
Importantly, the genetic deletion, RNAi-mediated depletion, or
pharmacological inhibition of p53 can all elicit autophagy induc-
tion; moreover, p53 inhibition promotes cell survival in response
to glucose starvation through autophagy. Based on these results
one can hypothesize that, upon p53 deletion in tumors, elevated
autophagy will provide a survival advantage to malignant cells in
response to unfavorable conditions found in the tumor
microenvironment.
The above studies demonstrate how multiple cancer-associated
pathways regulate autophagy. Importantly, one must recognize
that these signaling pathways do not function independently. In-
stead, a signaling network is formed by constant crosstalk among
the different pathways; furthermore, it is likely that certain signals
will be dominant over others during speciﬁc aspects of oncogenic
transformation and tumor progression. For example, although
oncogenes such as activated PI3K have inhibitory effects on autoph-
agy induction, when tumor cells encounter stresses, such as lack of
nutrients or energy, the inhibitory effects of this oncogenic PI3K on
autophagy may be overridden by signals targeting downstream
effectors (such as mTORC1). Similarly, p53 can also induce autoph-
agy despite the presence of oncogenes, for example, through Sestrin
expression. In this case, AMPK-mediated TSC activation overrides
oncogene-induced TSC inhibition, resulting in decreased mTORC1
activity. Thus, the ultimate induction or inhibition of autophagy
in cancer cells reﬂects the integration of signals resulting from
intracellular perturbations mediated by individual oncogenes and
tumor suppressors as well as extracellular cues, both micro-envi-
ronmental and iatrogenic, impinging on the tumor cell.5. Autophagy and cancer therapy
Increased autophagy is often observed in tumor cells in re-
sponse to chemotherapy and radiation. The majority of studies
indicate that autophagy inhibition sensitizes tumor cells to a wide
spectrum of cancer therapies, while others show that treatment-
induced tumor cell death requires intact autophagic machinery.
In this section, we will overview how the manipulation of autoph-
agy potentially inﬂuences treatment outcomes in cancer.
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ical inhibitors such as 3-methyladenine (3-MA), baﬁlomycin A1
(BafA), and chloroquine (CQ). 3-MA is purported as an inhibitor
of class III PI3K, Vps34 [29]. Together with its regulator p150,
Vps34 is involved in a variety of intracellular membrane modeling
events, including autophagosome isolation membrane formation
[39]. Hence, 3-MA inhibits autophagy at an early stage, the seques-
tration step. In contrast, BafA, a vacuolar H+-ATPase inhibitor, pre-
vents lysosomal function, thus blocking autophagosome
degradation, a late stage of the process [65]. Similarly, CQ, a weak
base that can be trapped in acidic vesicles and elevate intralysoso-
mal pH [66], also blocks cargo degradation [67,68]. Although these
compounds can effectively suppress autophagy and are widely
touted as autophagy inhibitors, none are speciﬁc for autophagy. In-
stead, these drugs have multiple off-target effects and modulate
other cellular activities, such as endocytosis, intracellular trafﬁck-
ing, and lysosomal biogenesis and function. A more direct evalua-
tion of autophagy-dependent effects in response to therapies can
be achieved by loss-of-function approaches directed at essential
autophagy genes (e.g. atg7, atg5, beclin-1/atg6).
5.1. Autophagy inhibition promotes chemotherapeutic efﬁcacy
High levels of autophagy observed in tumor cells following anti-
cancer treatment commonly represent an adaptive response that
enables tumor cells to survive the therapeutic insult [2]. Thus, it
is logical to hypothesize that autophagy inhibition will synergize
with other chemotherapies and more effectively eliminate cancer
cells. Indeed, abundant recent work supports this notion in multi-
ple tumor types and in response to diverse chemotherapeutic
agents, highlighting the possibility of targeting autophagy as adju-
vant therapy for cancer. The effect of inhibiting autophagy in com-
bination with current anti-cancer therapies has been tested in
multiple tumor models, including glioma [30,69–71], multiple
myeloma [72], breast [73,74], colon [75,76], and prostate cancer
[77]. Table 1 provides a partial list of such studies. Readers are also
referred to recent reviews for additional information [78,79].
Among these studies, one striking example demonstrating the
efﬁcacy of autophagy inhibition is in chronic myelogenous leuke-
mia (CML), a major subtype of leukemia in adults. The disease is
driven by a chromosomal translocation that produces the fusion
protein BCR/ABL, resulting in a constitutively active tyrosine kinase
that promotes both cell proliferation and survival. CML patients
have been successfully treated with imatinib (Gleevac), a tyrosine
kinase inhibitor (TKI) that inhibits BCR/ABL. However, imatinibTable 1
Autophagy inhibition during cancer chemotherapy.
Cancer type Primary treatment Target
Breast Trastuzumab Her2
CPT DNA topoiso
CML Imatinib BCR/ABL
INNO-406 BCR/ABL
SAHA HDAC
Colon Vorinostat HDAC
Radiation DNA damag
Glioma AKTi-1/2 AKT
PI-103 PI3K, mTOR
Imatinib Tyrosine kin
Radiation DNA damag
Radiation DNA damag
Malignant rhabdoid tumor FK228 HDAC
Multiple myeloma 8-Aminoadenosine DNA synthe
Prostate ADI-PEG20 Arginine in
Abbreviations: BafA, baﬁlomycin A1; CPT, camptothecin; CQ, chloroquine; HDAC, histon
target of rapamycin; PI3K, phosphoinositide 3-kinase; RNAi, RNA interference (ATG targresistance is a common problem in CML patients, which is partly
due to development of mutations in the Abl kinase domain, and
the relative insensitivity of CML stem cells to TKIs [80,81]. Even
in patients with robust response to imatinib treatment, residual
disease is still detectable, indicating CML stem cells are not elimi-
nated [82].
Imatinib has been shown to induce autophagy in a dose-depen-
dent manner in various cell lines [83]. Recently, the co-treatment
of imatinib with CQ was demonstrated to signiﬁcantly augmented
cell death in CML cells [80,84]. Similar results were also obtained
using RNAi against essential autophagy genes, atg5 and atg7, prov-
ing a direct link between autophagy inhibition and sensitization to
cell death. More importantly, imatinib plus CQ enhanced cell death
in primary cells isolated from patients at three distinct disease
stages, including an individual that was newly diagnosed, one
undergoing imatinib treatment, and a relapse patient carrying an
imatinib-resistant mutation. Whereas a previous study showed
imatinib alone does not efﬁciently kill CML progenitor cells [85],
imatinib/CQ co-treatment almost completely eradicated CML stem
cells in vitro, suggesting autophagy promoted CML stem cell sur-
vival during imatinib treatment. In support, an earlier study also
showed that targeting autophagy augmented the effect of SAHA,
an HDAC inhibitor, to overcome BCR/ABL mediated drug resistance
[81].
Two additional studies assessing the effect of CQ on lymphoma-
genesis in vivo demonstrate that CQ-mediated lysosomal inhibi-
tion enhances p53-mediated apoptosis [67,68]. In a Myc-driven B
cell lymphoma model using cells derived from p53ERTAM/p53ERTAM
mice, p53 expression can be switched on in lymphoma cells when
tamoxifen (TAM) is administered. CQ treatment alone modestly
impaired Myc-driven tumor growth, but did not elicit regression.
Similarly, inducing p53 expression with TAM induced rapid tumor
regression initially, but all tumors resumed growth several days la-
ter despite continued TAM administration. On the other hand,
TAM+CQ co-treatment signiﬁcantly delayed tumor recurrence. A
more detailed analysis implicated that CQ enhanced p53-mediated
apoptosis via inhibiting autophagy, as atg5 knockdown recapitu-
lated the effect of CQ on cell death upon p53 activation. Further-
more, the combined treatment of CQ and cyclophosphamide, the
ﬁrst-line therapy for human lymphomas, also signiﬁcantly delayed
tumor recurrence.
A second study tested the idea of using CQ as a cancer preven-
tion agent in El-Myc mice, a transgenic mouse model of human
Burkitt’s lymphoma. Interestingly, the epidemiological association
of CQ with reduced Burkitt’s lymphoma had been reported twoMethod(s) of autophagy inhibition Reference
3-MA, BafA, RNAi (LC3) [73]
merase 3-MA, BafA, RNAi (BECN1, ATG7) [74]
CQ, BafA, RNAi (ATG5, ATG7) [80]
CQ [84]
CQ, 3-MA [81]
CQ, RNAi (ATG7) [75]
e RNAi (BECN1, ATG3, ATG4B, ATG5) [76]
CQ [30]
CQ [30]
ases BafA [71]
e 3-MA, BafA RNAi (BECN1 ATG5) [70]
e 3-MA, BafA [69]
CQ [94]
sis CQ [72]
blood CQ, 3-MA, RNAi (BECN1) [77]
e deacetylases; MNNG, N-methyl-N0-nitro-N-nitrosoguanidine; mTOR, mammalian
et is in parentheses).
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CQ alone signiﬁcantly delayed lymphoma development, an effect
that was dependent on p53 expression. The cells death observed
in CQ-treated lymphoma cells exhibited hallmarks of both apopto-
sis and autophagy. Interestingly, blocking either apoptosis or
autophagy alone had little effect on CQ-mediated death; however,
when both processes were simultaneously blocked, CQ-mediated
cell death was suppressed. Collectively, these studies suggest a
pro-survival role for autophagy that reduces p53-mediated apop-
tosis. Because p53 expression is often induced by diverse antican-
cer treatments, autophagy may serve as an adaptive response to
apoptosis stimulus and promote tumor cell survival. Thus, inhibit-
ing autophagy in this context may sensitize tumor cells to p53-
mediated cell death.
Among the autophagy inhibitors tested, the lysosomal inhibitor
CQ and its derivatives have gained special attention due to their
favorable pharmacological properties and because of their long his-
tory of use as anti-malarial agents and in diseases such as rheuma-
toid arthritis. Currently, multiple clinical trials using CQ as a
sensitizing reagent in combination with standard cancer therapies
are under evaluation in different tumor types, including lung can-
cer, glioblastoma multiforme, multiple myeloma, breast cancer,
melanoma, colon cancer, prostate cancer, and advanced solid tu-
mors unresponsive to chemotherapy (http://clinicaltrials.gov).
However, as discussed above, the cytotoxic effects of CQ and sim-
ilar agents may involve processes other than autophagy; hence,
further studies are needed to dissect the precise contributions of
autophagy inhibition when employing these anti-malarials in di-
verse clinical settings.
5.2. Autophagy-dependent cell death in cancer therapy
Although the concept of ‘‘autophagic cell death” in mammalian
cells remains highly controversial [87], studies do show that
autophagy is required for the efﬁcient killing of tumor cells in cer-
tain circumstances. In pursuit of new drugs to treat renal cell car-
cinoma (RCC), Giaccia and colleagues identiﬁed compound STF-
62247, which selectively kills von Hippel-Lindau (VHL) deﬁcient
(a tumor suppressor gene lost in 75% of RCCs) cells in a synthetic
lethal manner [88]. STF-62247 caused autophagy induction and
massive vacuolization in VHL-deﬁcient RCC cells with no apparent
DNA damage or apoptosis. Blocking autophagy with 3-MA or
silencing atg5, atg7, or atg9 increased cell survival, supporting that
STF-62247 induces an autophagy-dependent cell death in these
cells.
In addition, D9-tetrahydrocannabinol (THC) can also induce cell
death in glioma cells through the stimulation of autophagy [89]. In
this study, THC treatment-induced ER stress and inhibited the AKT/
mTOR pathway. Genetic deletion of atg5 or RNAi-mediated deple-
tion of atg1 partially protected cells from death during THC treat-
ment. Interestingly, blocking apoptosis also prevented cell death
to a degree similar to atg5 deletion, which led the authors to spec-
ulate that autophagy is required for robust apoptosis induction in
response to THC. In support, knockdown of atg genes prevented
caspase-3 activation, and xenograft tumors formed by transformed
atg5/ ﬁbroblasts were resistant to THC-induced apoptosis. Thus,
THC-induced autophagy may promote the apoptosis of cancer cells
rather than directly cause their death.
The coordination of autophagy and apoptosis was also observed
in a recent study with melanoma cells [90]. The classic double-
stranded RNA mimic polyinosine–polycytidylic acid complexed
with polyethyleneimine ([PIC]PEI) potently killed melanoma cells
both in vitro and in vivo, and both autophagy and apoptosis were
required for inducing efﬁcient cell death. Notably, [PIC]PEI induced
rapid and persistent endocytic ﬂux in melanoma cells. When
autophagy was inhibited via BafA, CQ or atg5 deletion, cell deathwas suppressed. Interestingly, cell death was also signiﬁcantly re-
duced in melanoma cells treated with caspase-inhibitors or in cells
doubly deﬁcient for Bax and Bak, two multi-domain Bcl-2 family
members required for apoptosis, without affecting autophagy
induction. Based on these results and the observed time lag be-
tween autophagy induction (2–5 h post-treatment) and ﬁnal cell
collapse (at 24–48 h), the authors speculated that early and persis-
tent autophagy induction is required for apoptosis activation at a
subsequent stage. These observations illustrate the complex inter-
play between autophagy and apoptosis.
How then do we reconcile the seemingly conﬂicting roles of
autophagy on cell death in response to cancer therapy? Multiple
factors should be considered before drawing conclusions. For
example, although 3-MA and BafA are both considered autophagy
inhibitors, when used with temozolomide (TMZ) to treat glioma
cells, two opposite outcomes occurred. 3MA suppressed whereas
BafA enhanced TMZ-mediated cell death [91]. This indicates a
stage-speciﬁc consequence for autophagy inhibition, since 3-MA
and BafA inhibit the early and late stages of autophagy, respec-
tively [71]. Also, autophagy can exert both pro- or anti-apoptotic
effects in the same cells depending on the death stimulus adminis-
tered [92]. Furthermore, when genetically modiﬁed cells (e.g. ATG
deﬁcient cells) are used, other forms of autophagy, such as chaper-
one-mediated autophagy or microautophagy, may compensate for
the loss of macroautophagy and thus, inﬂuence tumor cell killing in
unexpected ways [93]. Moreover, in limited circumstances, it does
appear that both autophagy and apoptosis are needed to kill cells;
in such situations, stimulating autophagy may enhance drug cyto-
toxicity [90]. Finally, due to the lack of autophagy speciﬁc inhibi-
tors, the majority of studies have been conducted with
pharmacological agents with known off-target effects beyond
autophagy. Development of autophagy speciﬁc inhibitors, such as
small molecules targeting kinases (e.g. ULK1) or proteases (e.g.
Atg4B) required for autophagy induction, may help determine
the precise role of autophagy in cancer treatment.
In summary, the papers discussed above support that targeting
autophagy in combination with current cancer treatments is a
promising therapeutic strategy. However, due to the contrasting
roles autophagy plays during cancer initiation and progression,
the use of autophagy inhibitors should be tailored to speciﬁc tumor
contexts and in combination with speciﬁc therapeutics.6. Concluding remarks
Numerous links between deregulated autophagy and human
diseases have emerged. In cancer, current evidence supports that
autophagy suppresses tumorigenesis, particularly during the early
stages of tumor initiation. However, in established tumors, autoph-
agy can function as a survival pathway in response to stresses im-
posed during cancer progression and due to chemotherapy.
Accordingly, autophagy inhibition as an adjuvant to standard can-
cer therapy may increase treatment efﬁcacy in some tumor types.
Although such experimental ﬁndings have therapeutic implica-
tions, the clinical utility of modulating autophagy in human can-
cers still remains unclear. Notably, the efﬁcacy of lysosomal
agents that inhibit autophagy, such as CQ, is probably tumor-type
speciﬁc, and it remains unclear if long-term autophagy inhibition
may elicit untoward side effects in real patients. Ongoing clinical
trials should provide valuable information on whether and how
to manipulate autophagy during cancer treatment.
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